FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200492751> ?p ?o ?g. }

• W4200492751 endingPage "943" @default.
• W4200492751 startingPage "929" @default.
• W4200492751 abstract "Background: Bone is a frequent site of metastases from breast cancer, but existing therapeutic options are not satisfactory. Although osteoblasts have active roles in cancer progression by assisting the vicious bone-destructive cycle, we employed a counterintuitive approach of activating pro-tumorigenic Wnt signaling and examined the paradoxical possibility of developing osteoblast-derived tumor-suppressive, bone-protective secretomes. Methods: Wnt signaling was activated by the overexpression of Lrp5 and β-catenin in osteoblasts as well as a pharmacological agent (BML284), and the therapeutic effects of their conditioned medium (CM) were evaluated using in vitro cell cultures, ex vivo breast cancer tissues, and a mouse model of osteolysis. To explore the unconventional regulatory mechanism of the action of Wnt-activated osteoblasts, whole-genome proteomics analysis was conducted, followed by immunoprecipitation and gain- and loss-of-function assays. Results: While osteoblasts did not present any innate tumor-suppressing ability, we observed that the overexpression of Lrp5 and β-catenin in Wnt signaling made their CM tumor-suppressive and bone-protective. The growth of breast cancer cells and tissues was inhibited by Lrp5-overexpressing CM (Lrp5 CM), which suppressed mammary tumors and tumor-driven bone destruction in a mouse model. Lrp5 CM also inhibited the differentiation and maturation of bone-resorbing osteoclasts by downregulating NFATc1 and cathepsin K. The overexpression of Lrp5 upregulated osteopontin that enriched Hsp90ab1 (Hsp90 beta) and moesin (MSN) in Lrp5 CM. Hsp90ab1 and MSN are atypical tumor-suppressing proteins since they are multi-tasking, moonlighting proteins that promote tumorigenesis in tumor cells. Importantly, Hsp90ab1 immuno-precipitated latent TGFβ and inactivated TGFβ, whereas MSN interacted with CD44, a cancer stem-cell marker, as well as fibronectin 1, an ECM protein. Furthermore, Hsp90ab1 and MSN downregulated KDM3A that demethylated histones, together with PDL1 that inhibited immune responses. Conclusion: In contrast to inducing tumor-enhancing secretomes and chemoresistance in general by inhibiting varying oncogenic pathways in chemotherapy, this study presented the unexpected outcome of generation tumor-suppressive secretomes by activating the pro-tumorigenic Wnt pathway. The results shed light on the contrasting role of oncogenic signaling in tumor cells and osteoblast-derived secretomes, suggesting a counterintuitive option for the treatment of breast cancer-associated bone metastasis." @default.
• W4200492751 created "2021-12-31" @default.
• W4200492751 creator A5008017308 @default.
• W4200492751 creator A5015552421 @default.
• W4200492751 creator A5030027697 @default.
• W4200492751 creator A5061304782 @default.
• W4200492751 creator A5062739921 @default.
• W4200492751 creator A5081940051 @default.
• W4200492751 creator A5091188222 @default.
• W4200492751 date "2022-01-01" @default.
• W4200492751 modified "2023-10-14" @default.
• W4200492751 title "Suppression of breast cancer-associated bone loss with osteoblast proteomes via Hsp90ab1/moesin-mediated inhibition of TGFβ/FN1/CD44 signaling" @default.
• W4200492751 cites W1431954835 @default.
• W4200492751 cites W1671744717 @default.
• W4200492751 cites W1864373894 @default.
• W4200492751 cites W1913462480 @default.
• W4200492751 cites W1975953388 @default.
• W4200492751 cites W1984736888 @default.
• W4200492751 cites W1996576348 @default.
• W4200492751 cites W2001310748 @default.
• W4200492751 cites W2011855824 @default.
• W4200492751 cites W2019390346 @default.
• W4200492751 cites W2021868946 @default.
• W4200492751 cites W2027560347 @default.
• W4200492751 cites W2037100155 @default.
• W4200492751 cites W2082909405 @default.
• W4200492751 cites W2095782040 @default.
• W4200492751 cites W2102969047 @default.
• W4200492751 cites W2149109011 @default.
• W4200492751 cites W2155407283 @default.
• W4200492751 cites W2157618937 @default.
• W4200492751 cites W2338741450 @default.
• W4200492751 cites W2346687056 @default.
• W4200492751 cites W2489907708 @default.
• W4200492751 cites W2520632143 @default.
• W4200492751 cites W2591862276 @default.
• W4200492751 cites W2622329638 @default.
• W4200492751 cites W2784099857 @default.
• W4200492751 cites W2790339676 @default.
• W4200492751 cites W2793867406 @default.
• W4200492751 cites W2804268743 @default.
• W4200492751 cites W2804660096 @default.
• W4200492751 cites W2829837434 @default.
• W4200492751 cites W2841068772 @default.
• W4200492751 cites W2884354555 @default.
• W4200492751 cites W2921396831 @default.
• W4200492751 cites W2925885584 @default.
• W4200492751 cites W2943402377 @default.
• W4200492751 cites W2969757932 @default.
• W4200492751 cites W3002686604 @default.
• W4200492751 cites W3004628704 @default.
• W4200492751 cites W3006477510 @default.
• W4200492751 cites W3011393170 @default.
• W4200492751 cites W3013322249 @default.
• W4200492751 cites W3042151980 @default.
• W4200492751 cites W3045786341 @default.
• W4200492751 cites W3120853873 @default.
• W4200492751 cites W3133945326 @default.
• W4200492751 cites W3137354412 @default.
• W4200492751 cites W3182969438 @default.
• W4200492751 cites W3186281007 @default.
• W4200492751 cites W3212457141 @default.
• W4200492751 doi "https://doi.org/10.7150/thno.66148" @default.
• W4200492751 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34976221" @default.
• W4200492751 hasPublicationYear "2022" @default.
• W4200492751 type Work @default.
• W4200492751 citedByCount "23" @default.
• W4200492751 countsByYear W42004927512022 @default.
• W4200492751 countsByYear W42004927512023 @default.
• W4200492751 crossrefType "journal-article" @default.
• W4200492751 hasAuthorship W4200492751A5008017308 @default.
• W4200492751 hasAuthorship W4200492751A5015552421 @default.
• W4200492751 hasAuthorship W4200492751A5030027697 @default.
• W4200492751 hasAuthorship W4200492751A5061304782 @default.
• W4200492751 hasAuthorship W4200492751A5062739921 @default.
• W4200492751 hasAuthorship W4200492751A5081940051 @default.
• W4200492751 hasAuthorship W4200492751A5091188222 @default.
• W4200492751 hasBestOaLocation W42004927511 @default.
• W4200492751 hasConcept C121608353 @default.
• W4200492751 hasConcept C126322002 @default.
• W4200492751 hasConcept C137620995 @default.
• W4200492751 hasConcept C142669718 @default.
• W4200492751 hasConcept C1491633281 @default.
• W4200492751 hasConcept C182819311 @default.
• W4200492751 hasConcept C202751555 @default.
• W4200492751 hasConcept C2776292417 @default.
• W4200492751 hasConcept C2777783956 @default.
• W4200492751 hasConcept C2778260815 @default.
• W4200492751 hasConcept C2780246058 @default.
• W4200492751 hasConcept C502942594 @default.
• W4200492751 hasConcept C530470458 @default.
• W4200492751 hasConcept C54355233 @default.
• W4200492751 hasConcept C55493867 @default.
• W4200492751 hasConcept C62478195 @default.
• W4200492751 hasConcept C71924100 @default.
• W4200492751 hasConcept C86803240 @default.
• W4200492751 hasConcept C95444343 @default.
• W4200492751 hasConceptScore W4200492751C121608353 @default.

• next